Invention Grant
- Patent Title: Multivalent ligand for myotonic dystrophy
-
Application No.: US16641450Application Date: 2018-08-23
-
Publication No.: US11242326B2Publication Date: 2022-02-08
- Inventor: Yugang Bai , Steven C. Zimmerman , Auinash Kalsotra
- Applicant: The Board of Trustees of the University of Illinois
- Applicant Address: US IL Urbana
- Assignee: The Board of Trustees of the University of Illinois
- Current Assignee: The Board of Trustees of the University of Illinois
- Current Assignee Address: US IL Urbana
- Agency: Haukaas Fortius PLLC
- Agent Michael H. Haukaas
- International Application: PCT/US2018/047756 WO 20180823
- International Announcement: WO2019/040750 WO 20190228
- Main IPC: C07D251/64
- IPC: C07D251/64 ; A61K9/00 ; A61K9/06 ; A61K9/20 ; A61K9/48

Abstract:
Abnormally long r(CUG)n repeat expansion is believed to be the major cause of Myotonic dystrophy type 1 (DM1) because it binds to muscleblind-like 1 (MBNL 1) protein which regulates RNA splicing, leading to the mis-splicing of more than 100 pre-mRNAs. The rational design of oligomers with alternating bisamidine and melamine structure resulted in good binding affinity to the RNA target because of a multivalent effect. The oligomers also showed excellent activity in disrupting nuclear foci, reversing the mis-splicing of IR minigene, and sabotaging the toxic RNA biosynthesis. Excellent activity in Drosophila based DM1 models was also observed for the oligomers, rescuing the climbing ability of the flies upon oral treatment.
Public/Granted literature
- US2644208A Method for the manufacture of a screen for a television apparatus or the like Public/Granted day:1953-07-07
Information query